Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a specialty pharmaceutical company focused on developing abuse-deterrent formulations for controlled substances, principally opioid medications. The company entered public markets in 2021 through a de-SPAC merger with Laconia Acquisition Corp, a blank-check vehicle sponsored by Laconia Capital Group that completed its IPO in 2020. The May 2019 10-Q quarterly report on file predates the merger and documents the company's financials during its pre-public development stage. Ensysce operates within the specialty pharmaceuticals and drug-delivery technology sector. For full filing history, SPAC transaction details, and real-time data on Ensysce and comparable de-SPAC companies, sign up for a SpacDesk account today.